Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160450 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAASLC18A3MEN1KMT2A | |
| SCHEMBL2157992 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAASLC18A3MEN1KMT2A | |
| SCHEMBL11484818 | 0.98 | SLC18A3 (0.40) | ALDH1A1GAASLC18A3MEN1KMT2A | |
| SCHEMBL779656 | 0.93 | ALDH1A1 (0.38) | ALDH1A1GAASLC18A3SIGMAR1RECQL | |
| SCHEMBL1929909 | 0.80 | SLC18A3 (0.41) | ALDH1A1GAASLC18A3SIGMAR1TSHR | |
| SCHEMBL17090732 | 0.79 | BCHE (0.35) | GAAMEN1KMT2ANOS1 | |
| SCHEMBL9067373 | 0.78 | — | — | |
| SCHEMBL20562176 | 0.78 | ALDH1A1 (0.38) | ALDH1A1GAASLC18A3MEN1KMT2A | |
| SCHEMBL20562177 | 0.78 | ALDH1A1 (0.38) | ALDH1A1GAASLC18A3MEN1KMT2A | |
| SCHEMBL777679 | 0.78 | ATM (0.39) | ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118810-A1 | CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-11-16 | — | — | US | claimed |
| CN-116615193-A | Tumoxic acid monoester derivative as selective FABP5 inhibitor, pharmaceutical composition and application thereof | 纽约州立大学研究基金会 | 2023-08-18 | — | — | CN | claimed |
| EP-4225292-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | The Research Foundation for The State University of New York (US) | 2023-08-16 | — | — | EP | claimed |
| WO-2022076820-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2016011130-A1 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF 4-OXY-2-CYCLOHEXENONE AND 6-OXY-2-CYCLOHEXENONE COMPOUNDS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-01-21 | — | — | WO | claimed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | claimed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | claimed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | claimed |
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-5688990-A | FORMING CHEMICAL INTERMEDIATES FOR AZETIDINONE COMPOUNDS THAT INHIBIT CHOLESTEROL BIOSYNTHESIS FOR PREVENTION OF ATHEROSCLEROSIS | SHANKAR BANDARPALLE B (US) | 1997-11-18 | — | — | US | claimed |
| EP-0751934-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1997-01-08 | — | — | EP | claimed |
| EP-0701552-A1 | CONDENSED NITROGEN HETEROCYCLES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS, FUNGICIDES AND ANTIMYCOTICS | Hoechst Schering AgrEvo GmbH (DE) | 1996-03-20 | — | — | EP | claimed |
| WO-1995026334-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1995-10-05 | — | — | WO | claimed |
| WO-1994021613-A1 | CONDENSED NITROGEN HETEROCYCLES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS, FUNGICIDES AND ANTIMYCOTICS | HOECHST SCHERING AGREVO GMBH (DE) | 1994-09-29 | — | — | WO | claimed |
| US-5312950-A | Method for purification of alcohols | EASTMAN KODAK COMPANY (US) | 1994-05-17 | — | — | US | claimed |
| EP-0246196-B1 | OPTICALLY ACTIVE IRIDIUM COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1989-10-25 | — | — | EP | claimed |
| US-4851534-A | ENANTIOSELECTIVE HYDROGENATION CATALYST | CIBA-GEIGY CORPORATION (US) | 1989-07-25 | — | — | US | claimed |
| EP-0246196-A1 | Optically active iridium complexes, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1987-11-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ALDH1A1 1012/4885GAA 290/4885SLC18A3 2305/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ALDH1A1 635/4885GAA 3742/4885SLC18A3 875/4885 |
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | FABP5, FABP1, FABP4 | ALDH1A1 2048/4885GAA 3490/4885SLC18A3 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.